Rangering i aksjer
#35102
Imunon, Inc. is a biotechnology firm in the clinical development stage,... Imunon, Inc. is a biotechnology firm in the clinical development stage, dedicated to innovating and commercializing DNA-centric immunotherapies, vaccines, and targeted chemotherapy solutions. Its primary pipeline assets include GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a unique formulation of doxorubicin encapsulated in heat-activated liposomes, currently being assessed for a variety of cancer indications. Furthermore, the company is advancing two early-phase platform technologies aimed at developing nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA treatments. Established in 1982, Imunon, Inc. maintains its operational base in Lawrenceville, New Jersey.
Aksjekurs
$1.96
Sist synkronisert: 2022-09-20
Handel Imunon, Inc. (CLSN)
Pris CLSN pris med markedsverdi på B
Markedsverdi av Imunon, Inc.(CLSN)
Markedsverdi: $4.46M
Per August 2026 har Imunon, Inc. en markedsverdi på $4.46M. Dette gjør Imunon, Inc. til det 35102nd mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Imunon, Inc. fra 2008 til 2026
CLSN sammenlignet med topp 5 mest populære stocks
| Pris på CLSN |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.452T
|
+122,315,667.42%
|
|
|
|
|
$4.490T
|
+100,736,067.78%
|
|
|
|
|
$4.162T
|
+93,385,879.57%
|
|
|
|
|
$3.676T
|
+82,480,743.03%
|
|
|
|
|
$2.833T
|
+63,560,829.91%
|
